Wave Life Sciences Ltd. Ordinary Shares
$4.51
$0.04 (+1.01%)
$4.42Day Range$4.60
Key Statistics
Market Cap
$878.83M
Shares Outstanding
197.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 11, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$4.55
Day High
$4.60
Day Low
$4.42
Volume
2.99M
VWAP
$4.49
Prev Close
$4.46
Transactions
--
Acc. Volume
--
About Wave Life Sciences Ltd. Ordinary Shares
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
PHARMACEUTICAL PREPARATIONSSIC 2834317 employees7 STRAITS VIEW, SINGAPORE, U0, 018936617-949-2900IPO Nov 11, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001631574
- Composite FIGI
- BBG0248CHKR2
- Share Class FIGI
- BBG0248CHL36
- Ticker Root
- WVE
- SIC Code
- 2834
About Wave Life Sciences Ltd. Ordinary Shares (WVE) Stock
Wave Life Sciences Ltd. Ordinary Shares (WVE) closed the 2026-09-16 session at $4.50, up 1.01% versus the previous close (+0.04). The stock opened at $4.55 and traded between $4.42 and $4.60 during that session. Session trading volume was 3.0M shares. The volume-weighted average price (VWAP) is $4.49.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Wave Life Sciences Ltd. Ordinary Shares has a market capitalization of $878.8 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. WVE is listed on the XNAS exchange. The company employs approximately 317 people. Wave Life Sciences Ltd. Ordinary Shares is headquartered in SINGAPORE, U0. The recorded listing date is 2015-11-11.
On this page you can find market WVE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.